U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07332013) titled 'Urinary Titin Biomarker in DMD' on Nov. 06, 2025.
Brief Summary: A universal challenge in clinical investigation of novel therapeutics is the need for quantitative, objective biomarkers that directly address the mechanisms of disease and provide information relevant to clinically meaningful functional improvement. This has been a particular challenge in rare and slowly progressive diseases such as Duchenne Muscular Dystrophy (DMD).
The investigators hypothesize that urinary N-terminal fragment of titin (NTFT) corresponding to activity level/intensity will define a high-precision, non-invasive biomarker of systemic muscle injury to ...